These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 2834038)

  • 1. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
    Haglund C
    Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
    Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
    Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA 19-9 assay in patients with extrahepatic cholestatic jaundice.
    Barone D; Onetto M; Conio M; Paganuzzi M; Saccomanno S; Aste H; Pugliese V
    Int J Biol Markers; 1988; 3(2):95-100. PubMed ID: 3243982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dilemma of elevated CA 19-9 in biliary pathology.
    Tsen A; Barbara M; Rosenkranz L
    Pancreatology; 2018 Dec; 18(8):862-867. PubMed ID: 30249386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The contribution of CA 19-9 in the differential diagnosis between chronic pancreatitis and cancer of the pancreas].
    Van Gossum M; Delanghe A; Gerard M; Delcourt A; Deltenre M
    Acta Gastroenterol Belg; 1987; 50(1):91-4. PubMed ID: 3480672
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of bile cytology in the diagnostic management of patients with biliary tract obstruction.
    Cobb CJ; Floyd WN
    Acta Cytol; 1985; 29(2):93-100. PubMed ID: 2984868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
    Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
    Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
    Ohkura H; Sakawaki T
    Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour markers in pancreatic cancer.
    Haglund C; Roberts PJ; Kuusela P; Jalanko H
    Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunolocalization of tumours of the pancreas and biliary tree.
    Allum WH
    Baillieres Clin Gastroenterol; 1990 Dec; 4(4):853-67. PubMed ID: 2078788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CA 19-9, a new tumor marker].
    Akai S
    Rinsho Byori; 1983 Dec; 31(12):1300-2. PubMed ID: 6587136
    [No Abstract]   [Full Text] [Related]  

  • 18. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
    Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
    Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
    Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K
    Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.